HER2 Positive, Metastatic Biliary Tract Cancer
Conditions
Brief summary
To evaluate the efficacy and safety of inetetamab in combination with chemotherapy ± immunotherapy as a first-line treatment for HER2-positive advanced biliary tract cancer, providing theoretical evidence and practical guidance for further optimizing treatment regimens and improving therapeutic outcomes.
Interventions
DRUGInetetamab + Gemcitabine + Cisplatin ± PD-1/PD-L1 inhibitor
A 21-day cycle is used, with the initial dose of inetuximab at 8 mg/kg (IV), followed by 6 mg/kg (IV) on Day 1 of each subsequent cycle. Gemcitabine (1000 mg/m²) + cisplatin (25 mg/m²) are administered in combination on Day 1 and Day 8 of each cycle. The appropriate PD-1/PD-L1 inhibitor will be selected by the investigator based on the patient's specific condition, and its administration will strictly follow the dosing instructions provided in the relevant drug's package insert.
Sponsors
Eastern Hepatobiliary Surgery Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Males or females aged ≥18 years; * Histologically confirmed HER2-positive metastatic biliary tract cancer; * ECOG performance status of 0 to 1; * No prior treatment with anti-HER2 therapies; * Patients have not received any systemic anticancer treatment in the recurrent/metastatic setting; * Patients who have experienced disease recurrence more than 6 months after curative surgery; if adjuvant therapy (chemotherapy and/or radiotherapy) was received post-surgery, patients must have had recurrence more than 6 months after completion of adjuvant therapy; * Presence of at least one measurable lesion; * Adequate function of major organs as defined by the following criteria; * Estimated survival of ≥3 months; * Voluntary participation in this study, signing of the informed consent form, good compliance, and willingness to cooperate with follow-up.
Exclusion criteria
* Known allergy or contraindication to any component of the study drugs; * Previous treatment with anti-HER2 therapies; * Prior use of immunotherapy; * Use of immunosuppressive agents within 14 days before the first dose, except: Intranasal, inhaled, topical steroids, or local injections (e.g., intra-articular) Systemic corticosteroids ≤10 mg/day prednisone or equivalent Steroids for hypersensitivity reactions (e.g., premedication for CT scans) * Known active central nervous system metastases or carcinomatous meningitis; * Other malignancies within 5 years, excluding cured cervical carcinoma in situ, basal cell carcinoma, or squamous cell skin cancer; * Major surgery or significant trauma within 4 weeks before randomization, or planned major surgery; * Severe cardiac disease; * Resting dyspnea due to tumor progression or comorbidities, or requiring supplemental oxygen; * Neuropathy ≥ Grade I per NCI criteria; * Active interstitial lung disease (ILD) or pulmonary disease requiring bronchodilators; * History of immunodeficiency; * Participation in another drug trial within 4 weeks before screening; * Pregnant or breastfeeding women, or women of childbearing potential with a positive pregnancy test at screening; unwillingness to use effective contraception during and for 6 months after the study; * Any serious concomitant illness or conditions that may interfere with the planned therapy or render participation unsuitable.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective Response Rate (ORR) | 12 months |
Secondary
| Measure | Time frame |
|---|---|
| Progression-Free Survival (PFS) | 12 months |
| Disease Control Rate (DCR) | 12 months |
| Overall Survival (OS) | 24 months |
| Quality of Life Questionnaire-Core 30（QLQ-C30） | 24months |
| Adverse Event（AE） | 24 months |
Contacts
Primary ContactShen Feng, MD.; PhD
Backup ContactFeng Xie, MD
Outcome results
None listed